Compare VTR & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTR | BDX |
|---|---|---|
| Founded | 1983 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 43.0B |
| IPO Year | 2005 | 1997 |
| Metric | VTR | BDX |
|---|---|---|
| Price | $92.22 | $154.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $87.62 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | 2.38% | ★ 2.89% |
| EPS Growth | ★ 184.21 | N/A |
| EPS | 0.11 | ★ 0.25 |
| Revenue | $5,833,980,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $14.00 | N/A |
| Revenue Next Year | $8.35 | $3.02 |
| P/E Ratio | $840.95 | ★ $604.02 |
| Revenue Growth | ★ 18.47 | 8.24 |
| 52 Week Low | $65.12 | $140.11 |
| 52 Week High | $94.60 | $213.08 |
| Indicator | VTR | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 55.71 |
| Support Level | $84.56 | $153.27 |
| Resistance Level | $94.60 | $159.72 |
| Average True Range (ATR) | 1.92 | 4.14 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 69.89 | 61.84 |
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.